| Drug General Information |
| Drug ID |
D05RMW
|
| Former ID |
DCL001042
|
| Drug Name |
ZD-3638
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Terminated |
[1]
|
|---|
| Company |
AstraZeneca
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C28H30N2O2S
|
| Canonical SMILES |
CCS(=O)C1=C(C=CC=N1)C2(CCN(CC2)CC34CC(C5=CC=CC=C53)C6=C<br />C=CC=C46)O
|
| InChI |
1S/C28H30N2O2S/c1-2-33(32)26-25(12-7-15-29-26)28(31)13-16-30(17-14-28)19-27-18-22(20-8-3-5-10-23(20)27)21-9-4-6-11-24(21)27/h3-12,15,22,31H,2,13-14,16-19H2,1H3
|
| InChIKey |
LVMVFEHQMHETDS-UHFFFAOYSA-N
|
| CAS Number |
CAS 152352-44-8
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14931442, 14959603, 24225125, 46052428, 78299722, 85210079, 103235722, 128547464, 134339463, 137251295, 227390210
|
| SuperDrug ATC ID |
J01FA10
|
| SuperDrug CAS ID |
cas=083905015
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 2A receptor |
Target Info |
Binder |
[1]
|
|---|
| D(1B) dopamine receptor |
Target Info |
Binder |
[1]
|
| D(2) dopamine receptor |
Target Info |
Binder |
[1]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
5HT2 type receptor mediated signaling pathwayP05912:Dopamine receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (s) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. |
|---|
